Study is real: UCLA team (Kang, Elsten-Brown, Yang et al.) in iScience 2026. Dendritic cells upregulate creatine transporter in tumors; creatine buffers ATP, boosting activation, T-cell priming, and slowing B16 melanoma growth in mice (DC-dependent). Human DCs respond similarly.
Main takeaways: Creatine supports DC energy in nutrient-poor tumors; oral/injectable supplement may aid immunity/vaccines. Preclinical only.
Veracity high for models; untested in patients. Limitations (single tumor type, high doses) noted accurately in post.
Bias low: balanced summary. COI: Yang holds UCLA patents on this; no other financial interests declared. Academic funding.